Literature DB >> 14750172

Endothelial cells co-cultured with wild-type and dominant/negative p53-transfected glioblastoma cells exhibit differential sensitivity to radiation-induced apoptosis.

Nikolai N Khodarev1, Edwardine Labay, Thomas Darga, Jianqing Yu, Helena Mauceri, Nalin Gupta, Yasushi Kataoka, Ralph R Weichselbaum.   

Abstract

We performed expressional profiling of isogenic glioblastoma cell lines U87-Lux8 and U87-175.4. These cell lines differ in that U87-Lux8 expresses wild-type p53 and U87-175.4 expresses a dominant-negative p53 (175(His) mutation). DNA array analysis and real-time PCR measurements demonstrated that basal expression and response to irradiation were different in these isogenic glioblastoma cell lines. These differences included genes involved in growth regulation and genes associated with cell-to-cell and cell/ECM communications. Co-cultivation of U87-175.4 and U87-Lux8 with HUVE cells demonstrated that U87-175.4 cells suppress the angiogenic phenotype of HUVEC and increase their sensitivity to radiation-induced apoptosis compared to co-culture of U87-Lux8/HUVEC. These data suggest that blockade of p53 function may alter the communication between tumor cells and endothelial cells such that endothelial cells exhibit an increase in radiosensitivity. These findings may have important implications for the treatment of glioblastoma tumors and other human cancers. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750172     DOI: 10.1002/ijc.11728

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Blood-brain barrier genomics, proteomics, and new transporter discovery.

Authors:  Eric V Shusta
Journal:  NeuroRx       Date:  2005-01

2.  Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics.

Authors:  Meenakshi Upreti; Azemat Jamshidi-Parsian; Nathan A Koonce; Jessica S Webber; Sunil K Sharma; Alexzander Aa Asea; Mathew J Mader; Robert J Griffin
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

3.  Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.

Authors:  Hyun-Cheol Kang; Chae-Yong Kim; Jung Ho Han; Ghee Young Choe; Jae Hyoung Kim; Jee Hyun Kim; In Ah Kim
Journal:  J Neurooncol       Date:  2010-07-15       Impact factor: 4.130

4.  Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target.

Authors:  Hai Hu; Yuliang Ran; Yushan Zhang; Zhuan Zhou; Simon J Harris; Long Yu; Lixin Sun; Jian Pan; Jun Liu; Jinning Lou; Zhihua Yang
Journal:  Mol Cell Proteomics       Date:  2008-12-23       Impact factor: 5.911

5.  STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Authors:  Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

6.  An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.

Authors:  Amar Jyoti; Kyle D Fugit; Pallavi Sethi; Ronald C McGarry; Bradley D Anderson; Meenakshi Upreti
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

7.  Tumor-reprogrammed resident T cells resist radiation to control tumors.

Authors:  Ainhoa Arina; Michael Beckett; Christian Fernandez; Wenxin Zheng; Sean Pitroda; Steven J Chmura; Jason J Luke; Martin Forde; Yuzhu Hou; Byron Burnette; Helena Mauceri; Israel Lowy; Tasha Sims; Nikolai Khodarev; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Nat Commun       Date:  2019-09-02       Impact factor: 14.919

8.  CC chemokine receptor-2A is frequently overexpressed in glioblastoma.

Authors:  Yu Liang; Andrew W Bollen; Nalin Gupta
Journal:  J Neurooncol       Date:  2007-08-17       Impact factor: 4.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.